ClinicalTrials.gg

Program

Artesunate

Also written as “Artesunate + Amodiaquine”, “Artesunate ointment” and “Artesunate vaginal insert”.

Its studies are mostly in Malaria · Papillomavirus Infections · Malaria, Falciparum · Cytomegalovirus Infections · Vulvar Diseases, led by 7 companies.

Furthest: phase 4, since Mar 8, 200717 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi60 open or runningphase 4since Mar 8, 2007Apr 18, 2006none ahead
Frantz Viral Therapeutics44 open or runningphase 2since Sep 19, 2019Sep 19, 2019Dec 2026phase 2 · NCT06075264
Metanoic Health22 open or runningphase 2since Jul 7, 2025Jul 7, 2025Jun 30, 2027phase 2 · NCT07095478
Shin Poong Pharmaceutical20 open or runningphase 2since Sep 13, 2018Sep 13, 2018none ahead
Amivas11 open or runningphase 2since Feb 25, 2025Feb 25, 2025May 31, 2028phase 2 · NCT06853184
Pfizer10 open or runningphase 1since May 4, 2009May 4, 2009none ahead
Teva Pharmaceutical Industries10 open or runningphase 4since Sep 10, 2009Sep 10, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Apr 18, 2006.

  1. Oct 10, 2006Phase 1 study in MalariaSanofi · NCT00386503 · 22 enrolled · France
  2. Mar 8, 20072 phase 4 studies in MalariaSanofi · NCT00445796, NCT00452907
  3. May 4, 2009Pfizer's first study: phase 1 study in Malaria, FalciparumNew to PfizerPfizer · NCT00894374 · 40 enrolled · Singapore
  4. Sep 10, 2009Teva Pharmaceutical Industries's first study: phase 4 study in MalariaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00978172 · 220 enrolled · Cameroon
  5. Dec 1, 2009Phase 4 study in MalariaSanofi · NCT01023399 · 580 enrolled · Côte D'Ivoire
  6. Jun 20, 2011Phase 3 study in MalariaSanofi · NCT01378286 · 380 enrolled · Brazil
  7. Sep 13, 2018Shin Poong Pharmaceutical's first study: phase 2 study in Malaria, FalciparumNew to Shin Poong PharmaceuticalShin Poong Pharmaceutical · NCT03814616 · 300 enrolled · Gambia, Zambia
  8. Sep 19, 2019Frantz Viral Therapeutics's first study: phase 2 study in Papillomavirus InfectionsNew to Frantz Viral TherapeuticsFrantz Viral Therapeutics · NCT04098744 · 78 planned · United States
  9. Aug 26, 2020Phase 2 study in COVID-19Shin Poong Pharmaceutical · NCT04532931 · 192 enrolled · South Africa
  10. Sep 22, 2022Phase 2 study in Papillomavirus InfectionsFrantz Viral Therapeutics · NCT05555862 · 17 enrolled · United States
  11. Oct 4, 2023Phase 2 study in Vulvar DiseasesFrantz Viral Therapeutics · NCT06075264 · 27 planned · United States
  12. Jan 3, 2024Phase 2 study in Anal High-grade Squamous Intraepithelial LesionFrantz Viral Therapeutics · NCT06206564 · 48 planned · United States
  13. Feb 25, 2025Amivas's first study: phase 2 study in Cytomegalovirus InfectionsNew to AmivasAmivas · NCT06853184 · 90 planned · United States, Australia
  14. Jul 7, 2025Metanoic Health's first studies: 2 phase 2 studiesNew to Metanoic HealthMetanoic Health · NCT07095478, NCT07095309

Ahead

  1. Dec 2026Primary completion: phase 2 study in Vulvar DiseasesFrantz Viral Therapeutics · NCT06075264
  2. Dec 28, 2026Primary completion: phase 2 study in Papillomavirus InfectionsFrantz Viral Therapeutics · NCT05555862
  3. Dec 31, 2026Primary completion: phase 2 study in Anal High-grade Squamous Intraepithelial LesionFrantz Viral Therapeutics · NCT06206564
  4. Jun 30, 2027Primary completion: phase 2 study in CIN 2/3Metanoic Health · NCT07095478

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07095478CIN 2/3 · Malaysia2Not yet recruitingMetanoic HealthJun 30, 202728
NCT07095309Intestinal Neoplasms · Malaysia2Not yet recruitingMetanoic HealthAug 30, 2032120
NCT06853184Cytomegalovirus Infections · United States, Australia2RecruitingAmivasMay 31, 202890
NCT06206564Anal High-grade Squamous Intraepithelial Lesion · United States2RecruitingFrantz Viral TherapeuticsDec 31, 202648
NCT06075264Vulvar Diseases · United States2RecruitingFrantz Viral TherapeuticsDec 202627
NCT05555862Papillomavirus Infections · United States2Active, not recruitingFrantz Viral TherapeuticsDec 28, 202617
NCT04532931COVID-19 · South Africa2CompletedShin Poong PharmaceuticalAug 5, 2021192
NCT04098744Papillomavirus Infections · United States2RecruitingFrantz Viral TherapeuticsJul 31, 202678
NCT03814616Malaria, Falciparum · Gambia, Zambia2UNKNOWNShin Poong PharmaceuticalOct 2019300
NCT01378286Malaria · Brazil3CompletedSanofiJun 2013380
NCT01023399Malaria · Côte D'Ivoire4CompletedSanofiOct 2013580
NCT00978172Malaria · Cameroon4CompletedTeva Pharmaceutical Industries220
NCT00894374Malaria, Falciparum · Singapore1CompletedPfizerAug 200940
NCT00452907Malaria · Mali4CompletedSanofiJun 2007780
NCT00445796Malaria · Cameroon, Senegal4CompletedSanofi300
NCT00386503Malaria · France1CompletedSanofiDec 200622
NCT00316329Malaria · Cameroon, Madagascar, Mali and more3CompletedSanofi1,032

How it is read

Names in the registry

  • “Artesunate”, 6 entries
  • “Artesunate + Amodiaquine”, 3 entries
  • “Artesunate ointment”, 2 entries
  • “Artesunate vaginal insert”, 1 entry
  • “Artesunate-amodiaquine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.